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measurements in each 6 hour segment. Mean slopes for each segment are
presented.
We conclude that myocardial infarction has an important influence on dy-
namic OT behaviour. Slopes during the day, the evening an the night are
steeper compared to slopes in normal individuals.
Beta-blocker therapy results in a significant decrease of OT-slope after my-
ocardial infarction and tends to normalize the rate dependent changes of the
OT interval.
15% as haVing severe CAD. In this asymptomatic population, 228 En's and
7 coronary angiograms were performed in order to identify 1 individual with
severe CAD. Using Medicare reimbursement of $70 for En and $1500 for
angiography, the cost of screening per case of severe CAD identified would
be $26,460. Based on previously published data on survival with surgical and
medical therapy in patients with severe CAD, we estimate a cost of $120,000
to $180,000 per year of life saved with this screening approach. Conclusion:
This low yield suggests that screening asymptomatic individuals with En
may be costly and of little clinical value compared to other screening ap-
proaches.
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Cardiovascular Risk Factors Levels and Changes
Following Lifestyle Intervention In Families: The
British Family Heart Study
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1801-61 A New Noninvasive Test to Predict Inducible
Ventricular Tachycardia In Patients with Unexplained
Syncope: QT Dispersion
Leigh A. Hutchinson. Fidela Moreno, Frederick A. Ehlert. Jonathan S. Steinberg St.
Luke's-Roosevelt Hospital Center and Columbia University, New York, NY; WS Hospital,
Salt Lake City, ur
Regional disparities in ventricular repolarization are known to promote reen-
trant ventricular arrhythmias; recent work suggests that this may be as-
sessed noninvasively using OT/JT dispersion on the surface ECG. However,
very little data is available on its clinical use. We studied pts with unexplained
syncope to determine if inducible VT could be predicted by OT dispersion
(OTd, defined as OTmax-OTmin), OT standard deviation (OTstd), and equiv-
alent JT intervals. Values were also corrected using Bazetl's formula. We
enrolled 38 pts (22 M, age = 59 ± 18 yrs, 29% prior MI) who underwent pro-
grammed electrical stimulation (PES). Standard ECGs were recorded prior
to PES and analyzed by a computerized analyzer/digitizer. Results: Of the 38
pts, 9 (24%) had inducible sustained VT and 29 pts did not.
VT
NoVT
p value
Old
59 ± 18
46 ± 14
0.03
OTstd
18 ± 5
14± 4
002
JTd
63 ± 21
51 ± 12
008
JTstd
19 ± 4
15 ± 5
003
David Wood, Stephen Pyke, Ann-Louise Kinmonth, Simon Thompson, British
Family Heart Study Group. Department of Clinical Epidemiology, National Heart and
Lung Institute. London, UK
2373 families were recruited to a national randomised controlled trial of car-
diovascular screening and lifestyle intervention in 26 general practices in 13
towns across Britain. 2054 (87%) comprised both a male and female partner
and amongst these 1477 (72%) were represented at screening by both part-
ners. There was a significant association between reported cigarette smok-
ing habits in partners (odds ratio 6.1 95% CI4.6, 8.0) at baseline. Where both
partners were initially smokers, men were 5 times and women were 10 times
(p < 0.05) more likely to have quit where their partner had also quit. Body
mass index (BMI) measurements were correlated (r = 0.21, p < 0.0001) at
baseline and one year changes in BMI in partners were also significantly cor-
related (r = 0.20, p < 0.0001). Similar results were found for systolic blood
pressure, blood cholesterol and blood glucose cross-sectionally (r = 0.14,
0.10, 0.13 respectively, p < 0.0005) and longitudinally (r = 0.14, 0.24, 0.19
respectively, p < 0.0001). Whilst the cross sectional inter-partner relation-
ships are weak the longitudinal results demonstrate the scope for cardio-
vascular intervention programmes to capitalize on the tendency of partners
to change together. Men and women most able to improve their risk factor
profile over a one year period tend to have partners who also improve sub-
stantially. Therefore, for lifestyle intervention programmes in middle aged
men and women, targeting a couple together rather than as individual pa-
tients may result in a greater reduction in cardiovascular risk factors through
mutual reinforcement of lifestyle changes.
Standard ORS, OT and OTc, and corrected dispersion intervals were not
significantly different between pts with and without inducible VT.
Conclusion: Confirming the relationship of dispersion of ventricular repo-
larization and ventricular reentry, several ECG parameters of dispersion were
associated with inducible VT in patients with unexplained syncope. OT dis-
persion is a novel and noninvasive measure of risk of VT.
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1802-1 I Clinical Value and Cost of Screening Exercise
Treadmill Testing In Asymptomatic Individuals
Louise Pilote, Michael S. Lauer, Fredric Pashkow. Thomas H. Marwick. James
D. Thomas Cleveland Clinic Foundation, Cleveland, OH
Background: Exercise treadmill testing (En) is frequently performed to
screen for coronary artery disease (CAD) in asymptomatic individuals; how-
ever, its clinical value is questionable. Methods: To evaluate the clinical value
of ETT, we examined a cohort of asymptomatic individuals undergoing En
at the Cleveland Clinic between September 1990 and December 1993. En
was abnormal if it exhibited any of the following; a 1 mm ST-T elevation or
depression, a drop in blood pressure ,=:10 mmHg, chest pain or failure to
reach a target heart rate. Any CAD was defined by at least 1 coronary seg-
ment with ,=:50% stenosis. Severe CAD was defined by the following: 1) left
main coronary artery with ,=:50% stenosis, 2) 3 vessels with ,=:70% steno-
sis or 3) proximal left anterior descending artery and 2 vessels with ,=:70%
stenosis. Results: During this period, 4335 En's were performed in individ-
uals with no cardiac symptoms. The average age was 53, 89% were male
and 16% had at least one cardiac risk factor. Fifteen percent exhibited an
abnormal En. Among those with an abnormal ETT, 14% underwent coro-
nary angiography while among those with a negative En, 1% underwent
angiography. Coronary angiography identified 56% as having any CAD and
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\802-31 Treatment of Ventricular Arrhythmias After the
Cardiac Arrhythmia Suppression Trial (CAST): A
Survey of US Physicians
Yves Rosenberg. Eleanor Schron, Mario Stylianou, Albert Parker. National Heart,
Lung, and Blood InsMute, Bethesda, MD
To determine how US physicians treat patients with asymptomatic ventricu-
lar arrhythmias we conducted in fall 1992, after the publication of all CAST
results, a telephone survey of a randomly selected sample of 1072 American
generalists (G) and cardiologists (C). as part of a survey designed to study
how the results of three major cardiovascular clinical trials have influenced
medical practice.
730 physicians reported treating patients with ventricular arrhythmias. The
response rate was 63% (G: 65.3%, C: 60.9%). 44.2% of G, but only 22.1 %
of C would routinely use an antiarrhythmic drug (MD) or device to treat a
patient presenting ventricular premature depolarizations (VPD) who had a
myocardial infarction (MI) in the past six months (P < 0.001). 68.2% of G
and 40% of C would treat the same patient if he presented asymptomatic
nonsustained ventricular tachycardia (NSVT), p < 0.001. For the former con-
dition, the first choice drug would be a tl-blocker (G = 53.5%, C = 74%,p <
0.002). but 28.3% of G and 23.5% of C would use a class I MD (with <1 %
using a class IC).
36.9% of G and 16.1 % of C would treat a patient with coronary heart dis-
ease and an ejection fraction <40% presenting asymptomatic VPD, 66.2%
of G and 39.6% of Cwould treat asymptomatic NSVT (p < 0.001). For asymp-
tomatic VPD, the first choice drug is a Class I MD (G = 46.4%, C = 47.2%);
27.4% of G and 44.4% of C would prescribe a tl-blocker; 11.9% of G but no
C would prescribe a calcium-blocker. For the physicians treating NSVT, the
first choice drug is:
Class I Class II Class III Class IV Other Other
IA IB IC AAD
G(n ~ 145) 49% 0% 0.7% 172% 0% 9.7% 4.8% 11.7%
C(n = 91) 51.7% 12.1% 1.1% 29.7% 2.2% 2.2% 0% 1.1%
Total 50% 8.9% 0.8% 22% 0.8% 6.8% 3% 7.6%
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Conclusion: Many physicians reported use of class I AAD for the treatment
of post-MI patients with asymptomatic VPD in spite of the CAST findings.
This survey suggests that more effective methods of dissemination of clinical
trials results are needed.
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The Cost-Effectiveness of Pravastatin in Secondary
Prevention of Coronary Heart Disease
2:45
Care of Acute Myocardial Infarction by Non-invasive
and Invasive Cardiologists: Procedure Use, Cost,
and Outcome
Thomas G. Di Salvo, Sumita D. Paul, Conrad A. Smith, Michael!. Miyamoto,
Donald lIoyd-Jones, Kim A. Eagle, Patrick T. O'Gara Massachusetts General Hospital
and Harvard Medical School, Boston, MA
To determine if physician subspecialization influences practice style and
resource utilization, we prospectively studied 292 consecutive emergency
room admissions with MI under the care of noninvasive (NON, n = 213) or
invasive (INV, n = 791 cardiologists and compared the use of cardiac pro-
cedures, cost, and outcome. Results: Patient age, gender, CAD risk factors,
history of angina, MI, CHF, and prior cardiac catheterization, PTCA or CABG
were comparable. Presentation of MI. non-OIQ-wave MI, use of thrombolytic
therapy, peak CK, and EF did not differ. Procedures, cost, and length of stay
were as follows:
Talat Ashraf, Joel W. Hay, John R, Crouse, Michael H. Davidson, Curt D. Furberg,
Bertram Pitt, Ellison H. Wittels Emron, Inc., Warren, NJ: University ofSouthern
California, Los Angeles, CA
To determine the cost-effectiveness of pravastatin therapy in patients with
coronary heart disease, a projected risk model was developed that used
the results of the three-year, double blind, placebo controlled clinical trials:
Pravastatin Limitation ofAtherosclerosis in the Coronary Arteries (PLAC I) and
Pravastatin, Upids and Atherosclerosis in the Carotid Arteries (PLAC II). In
addition to measuring atherosclerotic progression, the PLAC studies eval-
uated four outcome variables: coronary heart disease death, non-coronary
heart disease death, fatal myocardial infarction, and non-fatal myocardial in-
farction in a patient population (mean age 60 years) with established coro-
nary heart disease and moderate low-density-lipoprotein cholesterol levels,
Pooled PLAC data analysis (n = 559) revealed a statistically significant (p <
0.05) difference in male non-fatal myocardial infarctions between the pravas-
tatin and placebo groups. The projected risk model utilized Framingham data
to project the risk of mortality 10 years post myocardial infarction. Markov
Process was used to estimate the life-years saved and cost. All costs and
benefits were discounted by 5%, Results are presented in the table below:
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Cost per Life-Year Saved
$19,082
$14,022
$10,630
Clinical and Economic Studies of PTCA
Patient Risk Profile
Male with CHD + 1Additional Risk Factor
Male with CHD + 2 Additional Risk Factors
Male with CHD + 3 Additional Risk Factors
Based on this model, pravastatin monotherapy in secondary prevention of
coronary heart disease has a cost-effectiveness ratio comparable to some of
the widely accepted medical interventions such as breast cancer screening,
$21,700, hydrochlorothiazide in the treatment of hypertension, $16,400, and
pneumococcal vaccine, $12,000.
Influence of Platelet GP lib/ilia Receptor
Inhibition with c7E3 on the Sequelae of
Dissection During Percutaneous Coronary
Revascularization
A. Michael Lincoff, Eric J. Topol, Robert M, Califf, Harlan F. Weisman, Nancy
M. Wildermann, Stephen G. Ellis. The Cleveland Clinic Foundation, Cleveland, OH;
Duke University. Durham, NC
The EPIC Trial tested the efficacy of the c7E3 monoclonal antibody to the
platelet GP IIblllla receptor in preventing ischemic events during "high-risk"
PTCA or atherectomy by randomizing 2099 pts to receive placebo (PL), c7E3
bolus (BO), or c7E3 bolus + 12 hr infusion (BO + IN). BO + IN of c7E3 pro-
duced a 35% reduction in the 30-day composite primary endpoint (death, MI,
urgent CABG, or re-PTCA) from 12.8% to 8.3% (p = 0,009) compared with
placebo. Although c7E3 would not be expected to prevent the mechanical
complication of coronary dissection, this agent may limit subsequent throm-
bus formation at dissection sites and thereby prevent progression to overt
closure, embolization, or ischemic clinical events.
The influence of c7E3 on adverse sequelae among pts who sustained dis-
section during EPIC was therefore investigated. Moderate (2-10 mm) or long
I> 10 mm) dissections, as determined by Angiographic Core Laboratory anal-
ysis, occurred in 40.1 %, 39,3%, and 42.5% of pts randomized to PL, BO, or
BO + IN, respectively.
11017-681
NON INV p-value
Thall Ell (%) 45 36 NS
Catheterization (%) 59 67 NS
CABG (all pts, %) 13 12 NS
PTCA (3VD, %) 17 35 NS
PTCA (1 or 2-VD, %) 39 60 <0.05
Total hospital days 14 17 <005
ICU days 31 5.4 <001
Hospital costs 1$) 19,400 25,500 0.01
Background: High plasma homocysteine concentration is a significant risk
factor for premature vascular disease in men, but the role in determining
coronary disease risk in women remains unclear.
Methods: Risk factors, including hypertension, hypercholesterolemia,
smoking, and diabetes were recorded in 228 patients (175 men, 53 women)
with angiographically documented coronary disease (2:70% stenosis of at
least one major coronary vessel), and 223 healthy controls (181 men, 42
women), Fasting total plasma homocysteine was measured in all subjects.
A high homocysteine concentrations was defined as a level greater than the
80th percentile, adjusted for gender.
Results: In univariate analysis, homocysteine correlated with age, but not
smoking, hypertension or hypercholesterolemia. Homocysteine values and
odds ratios based upon multivariate analysis were:
There were no differences between groups in the incidence of post-
MI complications (shock, pulmonary edema, post-MI angina, VTNF) or re-
versible thallium perfusion defects. Overall, 61 % of patients underwent car-
diac catheterization; there were an equal number of patients with 1, 2, and
3-vessel CAD in each group. Multivariate predictors of PTCA in patients with
1 or 2-vessel CAD were previous PTCA, Q-wave MI, and care by INV. Out-
come: In-hospital reinfarction and mortality (8.7% vs 12.7%) did not differ;
during median 12-month follow-up (96% of pts), reinfarction and mortality
(11.3% vs 10.3%) were similar, ConClusion: In this pilot study, subspecial-
ization impacted upon the cost of care of MI and led to increased PTCA in
patients with 1 or 2-vessel CAD; larger studies are needed to determine the
influence of subspecialization on long-term clinical outcomes.
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High Homocysteine Concentrations: An Independent
Risk Factor for Coronary Atherosclerosis in Women
Ellen Mayer, Dave Miller, Anjun Gupta, Steven E. Nissen, Donald W. Jacobsen,
Ralph Green, Kandice Kottke Marchant, Killian Robinson. The Cleveland Clinic
FoundaD'on, Cleveland, Ohio
Abrupt Closure 13% 7% 10% 0,080
Embolization < 1% 1% 1% 0.693
Primary Composite Endpoint 17% 12% 10% 0025
Death 3% 1% 1% 0.510
Myocardial Infarction 12% 6% 7% 0013
Emergency Re-PTCA 6% 5% 1% 0002
Emergency CABG 5% 3% 3% 0.350
Women Men
Patients Controls Patients Controls
Age 62 ± 12' 53 ± 10 61 ± 11' 51 ± 10
Homocysteine Levell/lmol!L) 127 ± 4.4' 102 ± 4.9 13.1 ± 4.3' 11.3 ± 30
Percent High Homocysteine 55,t 20 35' 20
Odds Ratio 3.2' NA 1.9' NA
Confidence Interval 1.2-£.4 NA 11-33 NA
* p < 0.01 V$ controls; t p < 0.05 vs male patients
Event PL (N = 278) BO IN = 273) BO + IN IN ~ 301) p-value
Conclusions: Mean homocysteine concentrations are higher in women
with coronary disease than age and sex matched controls. High homocys-
teine levels are more frequently seen in women than men and confer an
independent three-fold incremental risk of CAD.
Although c7E3 did not significantly diminish the risk of abrupt closure or
embolization among pts with moderate or long coronary dissections, potent
reduction in the incidences of MI and emergency repeat revascularization
may reflect ultimate stabilization of disrupted vascular segments during the
